test

Mario Sznol MD

Professor of Medicine (Medical Oncology); Clinical Research Program Leader, Melanoma Program, Yale Cancer Center; Co-Director, Yale SPORE in Skin Cancer

Clinical Interests

melanoma; immunologic therapy; renal cell (kidney) carcinoma; Phase I trials


Board Certifications

1985
Internal Medicine, Board Certified
1987
Medical Oncology, Board Certified

Patient Care Locations

 
mario_sznolfaculty-clinicsfalsetruetrue6truefalsefalse
 

Clinical Trials

Conditions Study Title
Lung and Melanoma, skin A Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases
Kidney A PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA
Expanded Access of MK-3475 in Metastatic Melanoma Patients with Limited to No Treatment Options
A phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has progressed after prior VEGFR Tyrosine Kinase Inhibitor Therapy
Melanoma, skin Phase I Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies

More Clinical Trials...

Edit Profile